Company intelligence / Profile preview
Senlang Bio
Shijiazhuang, Hebei, Chinasenlangbio.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Other
01
Overview
Senlang Bio is a clinical-stage biotechnology company focused on the development of innovative CAR-T cell therapies for hematological malignancies and solid tumors. Their lead product candidate, SENL101, has demonstrated significant efficacy in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). The company is also notable for its advancements in CD7-targeted CAR-T therapies for T-cell malignancies and is exploring multi-targeted and universal CAR-T technologies.
- Therapeutic areas
- OncologyHematology
- Modalities
- CAR-T cell therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
40 assets39 more assets in the full pipeline.
03
Partnerships
The Second Hospital of Hebei Medical UniversityTianjin First Central Hospital
Beyond the preview
Go deeper on Senlang Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Senlang Bio.